Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vch-222 + peginterferon alfa-2a + ribavirin
- Development stage
- Unknown
- Lead developer
- Vertex
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
**VCH-222 + peginterferon alfa-2a + ribavirin** is a combination therapy investigated for the treatment of chronic hepatitis C virus (HCV) infection. VCH-222 (also known as VX-222 or lomibuvir) is a novel, potent and selective non-nucleoside inhibitor of the HCV NS5B RNA-dependent RNA polymerase, disrupting viral replication[1][3][9]. Peginterferon alfa-2a is a pegylated form of interferon-alpha, acting as an immunomodulatory cytokine to enhance the host antiviral response, while ribavirin is a nucleoside analogue that inhibits viral RNA synthesis[2][4][6]. The combination targets multiple steps in the HCV lifecycle, aiming to improve sustained virologic response (SVR) rates compared to traditional therapies[1][2].
- Other names
- vch-222 + peginterferon alfa-2a + ribavirin
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)IFNAR (Immune system modulation via type I interferon receptor)vRNA (Coronavirus viral RNA)
Beyond the preview
Go deeper on vch-222 + peginterferon alfa-2a + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vch-222 + peginterferon alfa-2a + ribavirin.